Spain alzheimer’s therapeutics market valued at $93 Mn in 2022, projected to reach $73 Mn by 2030 with a 8.1% CAGR. One key factor propelling the market for Alzheimer's treatment medications is the rising incidence of Alzheimer's disease which is driven by an aging population. Biogen, Eisai Co, Janssen Pharmaceuticals, Novartis, Pfizer, Lundbeck, Merck & Co, AstraZeneca, Eli Lilly and STA Pharmaceutical are leading pharmaceutical companies currently operating in the market.
Spain alzheimer’s therapeutics market valued at $93 Mn in 2022, projected to reach $73 Mn by 2030 with a 8.1% CAGR.
Alzheimer's is a neurological condition that impairs memory, behavior, and mental health. Usually, it starts slowly, gets worse with time, and makes it harder for the individual to do daily tasks. Nerve cells in Alzheimer's disease die as a result of abnormal brain alterations such as plaque and tangle formation. Alzheimer's disease does not currently have a cure. In contrast, some drugs can help manage symptoms and enhance quality of life. To treat memory and cognitive issues, these medications, which include donepezil, rivastigmine, and memantine, modulate specific neurotransmitters in the brain. Furthermore, non-pharmacological approaches including maintaining a healthy lifestyle, engaging in social and cognitive activities, and fostering a supportive environment might improve overall illness management.
In Spain, there are over 900,000 people with various forms of cognitive decline, with Alzheimer's disease accounting for 60-70% of these cases, which translates to approximately 540,000 to 630,000 individuals with Alzheimer's as of 2022. The prevalence of Alzheimer's increases with age, affecting 2.4% to 6.9% of individuals aged 65 and above, and 15-20% of those aged 80 and beyond. The aging population in Spain is expected to lead to a substantial increase in Alzheimer's cases in the coming decades, with projections indicating a doubling of the affected population.
Phase 2 trials are presently being conducted by Roche and its Spanish partner, the Alzheimer's Diagnostic and Therapeutic Foundation (FISABIO), for BIIB037, a tau aggregation inhibitor that shows promise for treating moderate cognitive impairment linked to Alzheimer's disease. It is anticipated that the trials will yield findings in late 2024 or early 2025.
The Spanish startup Lumo Pharma is moving on with Phase 2 studies for LMTX-803, a medication that targets amyloid plaques and Tau pathology. Promising cognitive and functional benefits are suggested by initial evidence, which represents a significant advancement in the search for effective treatments for Alzheimer's disease.
Market Growth Drivers
Aging Population and Rising Life Expectancy: Spain's population is aging quickly, by 2050, there will be twice as many individuals over 65. Given that the likelihood of acquiring Alzheimer's disease rises with age, this will result in a notable rise in the population affected by the condition. Spain's increasing life expectancy is a result of better living conditions and healthcare, which also implies that more individuals are enduring Alzheimer's for longer periods, which increases the demand for pharmaceuticals treating Alzheimer's.
Emerging Disease-Modifying Therapies: To address the underlying causes of the illness, new treatments that attempt to delay or even reverse the course of the disease have been developed thanks to the tremendous progress made in research toward groundbreaking discoveries. In addition to approved Disease-Modifying Therapies (DMTs) like Leqembi and Aduhelm, promising prospects in the development pipeline are also fuelling industry excitement and propelling market expansion. These developments point to a paradigm-shifting time in Alzheimer's disease treatment and a movement toward more effective therapy.
Increased Awareness and Improved Diagnosis: In Spain, there is a growing public awareness of Alzheimer's disease, which is resulting in earlier diagnosis and a higher propensity to seek treatment. Advocacy initiatives, media attention, and campaigns are what are generating this awareness. Technological developments in biomarkers and diagnostic tools enable an earlier and more precise diagnosis of Alzheimer's disease, which opens the door to early intervention and the possibility of treating the illness in its early stages.
Market Restraints
Lack of Awareness and Stigma: The ongoing social stigma attached to dementia and Alzheimer's disease keeps many people from getting a diagnosis and treatment, especially despite the increasing number of awareness campaigns. This stigma is a major obstacle keeping the market from reaching a larger customer base.
Limited Efficacy and Uncertain Long-Term Benefits: The long-term sustainability and effectiveness of existing drugs, like Leqembi and Aduhelm, to delay cognitive deterioration is under question. Hesitancy can be caused by several things, including the lack of a convincing cure or solid proof of improved health.
High Cost of Drugs: The high cost of branded Alzheimer's medications like Exelon and Aricept places a significant financial burden on patients and their families, which may lead to treatment noncompliance, treatment abandonment, or a delayed diagnosis. The lack of reasonably priced generic substitutes further restricts access for those with lower incomes.
The Spanish Agency for Medicines and Medical Devices, also known as AEMPS, is primarily in charge of overseeing the country's healthcare policy and treatment drug regulations. AEMPS plays a vital role in guaranteeing the safety, effectiveness, and quality of medications in Spain and is managed by the Ministry of Health, Consumer Affairs, and Social Welfare (Ministerio de Sanidad, Consumo y Bienestar Social). AEMPS is in charge of assessing, approving, and monitoring pharmaceutical products, including medications used for treatment. It works in tandem with the European Medicines Agency (EMA) to ensure compliance with EU legislation. Its operations include pharmacovigilance, post-marketing surveillance, and regulatory clearance procedures.
Key Players
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Type
By Drug Name
By Drug Class
By End-Users
By Distribution Channel
Insights10 will provide you with the reports within 10 key parameters which are:
Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.
Stage I: Market Data Collection
Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.
Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.
Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:
Stage II: Market Data Analysis and Statistical Model
Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.
Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.
The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.
The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.
Data Triangulation & Validation:
Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.
We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.
Stage III: Interpretation and Presentation
Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)
Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.
Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.
Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.
The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
This report addresses
Need more?